Breaks Categories: News

FridayOct 13, 2023 2:27 pm

BioMedNewsBreaks — Octane Selects IBN as Official Media Partner for Upcoming Medical Innovation Forum

Octane, a convening organization of the Southern California technology and medical technology business ecosystem, is partnering with IBN (“InvestorBrandNetwork”), a pioneering corporate communications firm and content distributor, to provide key communications and coverage of Octane’s Medical Innovation Forum. According to the announcement, IBN will serve as Official Media Partner for the event, with IBN’s InvestorWire serving as the Official NewsWire. The two-day forum is slated for Oct. 25–26, 2023, in Irvine, California. Octane is committed to create and support a thriving business ecosystem in Southern California by fostering the growth of tech and medtech ventures; the organization has a goal of…

Continue Reading

ThursdayOct 12, 2023 3:48 pm

BioMedNewsBreaks – NextPlat Corp. (NASDAQ: NXPL) Announces Launch of OPKO Health Inc. (NASDAQ: OPK)-Branded Online Storefront

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced that, through a new e-commerce distribution agreement, it will enable the online sales of OPKO Health Europe, a subsidiary of OPKO Health (NASDAQ: OPK) products in China. Under the agreement terms, NextPlat will launch a OPKO Health-branded online storefront on Alibaba Group Holding Limited's (NYSE: BABA) Tmall Global e-commerce platform in China featuring an assortment of nutraceutical and veterinary products sold and distributed by OPKO Europe. “NextPlat’s focus is to enable companies across an array of high-growth sectors, such as health care and consumer products, to capitalize on the vast…

Continue Reading

ThursdayOct 12, 2023 1:36 pm

BioMedNewsBreaks – Octane’s Upcoming Forum to Feature Visionaries, Cutting-Edge Advances in Medical Technology Space

Octane, a strategic partner for emerging companies, today announced details of this year’s Octane 2023 Medical Innovation Forum. The two-day event is slated to take place at the Irvine Marriott in Irvine, California, on October 25-26, 2023. The forum will feature some of the medical technology sector’s most visionary speakers, granting access to invaluable educational opportunities, showcasing cutting-edge technological advances, and providing a prime networking platform to explore synergies and foster enduring partnerships among industry professionals. “Southern California is one of the country’s most dynamic and promising markets, and Octane aims to create more than 55,000 technology jobs by 2030…

Continue Reading

ThursdayOct 12, 2023 12:00 pm

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Enters into $4M Registered Direct Offering

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has entered into a definitive agreement for the issuance and sale shares of its common stock. Specifically, the agreement calls for the issue and sale of 2,424,243 shares of Class A common stock, or common stock equivalents, for $1.65 per share in a registered direct offering. The announcement also noted that a concurrent private placement calling for Longeveron to issue and sell unregistered Series A warrants to purchase up to 2,424,243 shares…

Continue Reading

ThursdayOct 12, 2023 11:13 am

BioMedNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Reaches Agreement Regarding Reorganization of Three US Subsidiaries

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, has announced a prepackaged reorganization of some of its subsidiaries. Those subsidiaries include RevitaLid Pharmaceutical Corp., RVL Pharmaceuticals Inc. and RVL Pharmacy, LLC. According to the announcement, a change of control transaction agreement was reached with their sole secured lenders, funds managed by Athyrium Capital Management (“Athyrium”) and other key stakeholders. The transaction will be made through through prepackaged bankruptcy cases that have begun in the U.S. Bankruptcy Court…

Continue Reading

WednesdayOct 11, 2023 1:42 pm

BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Appoints Intel Capital Cofounder to Board

Renovaro BioSciences (NASDAQ: RENB), a biotechnology corporation focusing on cell, gene and immunotherapy, has announced a new member of its board of directors. Avram Miller, cofounder of Intel Capital, will join the board and will also serve in an advisory role, bringing his invaluable experience to contribute to the company's strategy and business development efforts. Miller’s impressive decades-long career includes strategic and responsible roles in both the technology and medical industries. After spending 13 years in the medical science space, he moved to high tech where, in addition to cofounding Intel Capital, he served as the company’s corporate vice president of…

Continue Reading

WednesdayOct 11, 2023 1:34 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Rapid Pace of Enrollment in Potentially Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting enrollment of 229 participants in its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer; the company expects to ultimately enroll 243 in the study. Participants are being enrolled in 46 clinical trial sites across the United States, Italy, France, Spain and Switzerland. According to the announcement, CNS Pharmaceuticals is on track to achieve value-driving milestones before the end of the year, including…

Continue Reading

TuesdayOct 10, 2023 2:33 pm

BioMedNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT) Welcomes COO Jarrett Boon to Its Board of Directors

Safety Shot (NASDAQ: SHOT) today announced that Jarrett Boon, who has served as the company’s chief operating officer since August 2023, has been appointed to Safety Shot’s board of directors. Boon is leading the launch and growth of the company’s Safety Shot functional drink business this quarter. Boon was the co-founder and CEO of GBB Drink Lab, which developed Safety Shot, the first patented beverage that helps people feel better faster by reducing blood alcohol content and boosting clarity. “In the past few months since I’ve joined the company, our outstanding team has teed up the Safety Shot drink for…

Continue Reading

TuesdayOct 10, 2023 2:29 pm

BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Announces Strategic Board Appointments of Two Finance Industry Experts

Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, today announced the appointment of Leni Boeren and Ruud Hendriks as independent directors. Both Boeren and Hendriks bring extensive, high-level experience in finance and business. Boeren has a 40-year career in the financial sector, commencing with banking roles at Paribas and Rabobank before holding several director-level positions at Amsterdam exchanges and then Euronext. Hendriks brings more than 35 years of experience in the asset management industry, having held senior roles at some of the most established financial institutions.…

Continue Reading

TuesdayOct 10, 2023 2:22 pm

BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) to Serve as Gold Sponsor of Synchrony Symposia 2023

PaxMedica (NASDAQ: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions, today announced its Gold Sponsorship of The BRAIN Foundation's esteemed Synchrony Symposia 2023. The globally recognized event serves as a catalyst for translational research in autism and related neurodevelopmental disorders and brings together leading scientists, clinicians, biotech and pharmaceutical companies, venture partners, and community stakeholders to foster scientific advancements that can enhance the well-being and quality of life for individuals affected by ASD. “We are honored to support The BRAIN…

Continue Reading